Angela Jeannine Okragly is a prominent inventor based in Indianapolis, IN (US). She has made significant contributions to the field of biotechnology, particularly in the development of antibodies for treating allergic diseases. With a total of 2 patents, her work is paving the way for innovative treatments in this area.

Latest Patents

Okragly's latest patents include groundbreaking research on DNA molecules encoding anti-IL-33 antibodies. These antibodies are designed to bind and neutralize human IL-33, which plays a crucial role in allergic responses. The methods associated with these antibodies are particularly useful for treating conditions related to allergic diseases, including atopic dermatitis. Her second patent also focuses on anti-IL-33 antibodies and their applications in disease treatment, further emphasizing their potential in managing allergic conditions.

Career Highlights

Angela Okragly is currently employed at Eli Lilly and Company, a leading pharmaceutical firm known for its commitment to innovation in healthcare. Her work at Eli Lilly has allowed her to collaborate with some of the brightest minds in the industry, contributing to advancements in allergy treatment.

Collaborations

Some of her notable coworkers include Robert Jan Benschop and Julian Davies. Their collaborative efforts have been instrumental in driving forward the research and development of new therapeutic agents.

Conclusion

Angela Jeannine Okragly's contributions to the field of biotechnology, particularly in the development of anti-IL-33 antibodies, highlight her role as an innovator in allergy treatment. Her work continues to inspire advancements in medical science and improve the lives of those affected by allergic diseases.

Profile summary based on public USPTO records.